Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

38.9%

7 terminated/withdrawn out of 18 trials

Success Rate

58.8%

-27.7% vs industry average

Late-Stage Pipeline

22%

4 trials in Phase 3/4

Results Transparency

120%

12 of 10 completed trials have results

Key Signals

12 with results6 terminated

Enrollment Performance

Analytics

Phase 2
7(41.2%)
Phase 3
4(23.5%)
Phase 1
4(23.5%)
N/A
2(11.8%)
17Total
Phase 2(7)
Phase 3(4)
Phase 1(4)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT03949673Phase 2Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Role: collaborator

NCT02683239Phase 3Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

Role: collaborator

NCT05532358Phase 1Completed

A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)

Role: collaborator

NCT03691974Phase 2Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Role: collaborator

NCT03304379Phase 3Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Role: collaborator

NCT03161093Phase 3Completed

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Role: collaborator

NCT00326625Phase 2Completed

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT04358068Phase 2Terminated

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

Role: collaborator

NCT02092077Phase 2Terminated

A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children

Role: lead

NCT01123070Phase 1Completed

TL011 in Severe, Active Rheumatoid Arthritis Patients

Role: lead

NCT03285646Phase 3Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Role: collaborator

NCT03491904Phase 1Completed

To Assess the Patients' Ability to Self-Administer Fasinumab

Role: collaborator

NCT00745615Phase 2Terminated

An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Role: lead

NCT02907723Not ApplicableCompleted

Feasibility of Continuous Sleep Recording in Patients Undergoing Deep Brain Stimulation for Parkinson's Disease

Role: collaborator

NCT02552303Not ApplicableCompleted

The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia

Role: collaborator

NCT02835794Phase 1Withdrawn

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Role: collaborator

NCT02515643Unknown

Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients

Role: collaborator

NCT02029417Phase 2Terminated

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Role: collaborator

All 18 trials loaded